NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Cannot have received: myelosuppressive chemotherapy

must not have received within 2 weeks prior to registration

Cannot have received: biologic anti-neoplastics (not associated with reduced platelet or ANC counts, including retinoids)

must not have received within 7 days prior to registration

Cannot have received: monoclonal antibody

Exception: resolution of all toxicities required

must not have received last dose within 14 days of registration and resolution of all toxicities

Cannot have received: cellular therapy (modified T cells, NK cells, dendritic cells)

Exception: resolution of all toxicities required

must not have received within 3 weeks and resolution of all toxicities

Cannot have received: radiation therapy

must not have received small port radiation within 7 days prior to registration, large field radiation within 12 weeks, and 131I-MIBG therapy or other radiopharmaceutical within 6 weeks

Cannot have received: hematopoietic stem cell transplant (myeloablative)

none following myeloblative therapy within 6 weeks

Cannot have received: investigational agent

Any other investigational agents (covered under another IND) within 14 days

Cannot have received: strong CYP3A4 inducer or inhibitor

Strong inducers or inhibitors of CYP3A4